This is an exclusive BHB+ story.
BrainsWay Invests in Chicago Area Provider Hopemark Health
BrainsWay (Nasdaq: BWAY), the Burlington, Massachusetts-based maker of deep transcranial magnetic stimulation (TMS) and neurostimulation treatments for mental health conditions, has invested $1.5 million in Hopemark Health, an integrated mental health care provider.
Hopemark Health has six locations throughout the Chicago area and offers psychiatric care, telehealth, deep TMS, ketamine and Spravato treatment.
BrainsWay’s growth has surged in the last year and this latest investment is not the company’s first. The company recently announced a 35% year-over-year revenue growth during its first-quarter earnings call. Some of that growth has been driven by heightened popularity of TMS treatment, which has even led payers like Evernorth and Cigna to remove prior authorizations for this specific type of care.
In 2025, BrainsWay invested $3.3 million in Axis Integrated Mental Health, a mental health care provider that offers treatments similar to those of Hopemark Health, but across northern Colorado.
Its latest investment in Hopemark Health is part of its long-term strategy to “partner with growth-oriented clinical platforms” and to expand access to TMS treatments, BrainsWay CEO Hadar Levy shared in a statement.
Ampa’s total funding for portable TMS device reaches $25M
On the same front, Ampa, the company behind a portable, FDA-cleared neuromodulation TMS device, secured an undisclosed oversubscribed financing round, bringing its total raise to $25 million.
The latest funding will help the company accelerate the rollout and adoption of its Ampa One TMS system, which is actively used in 30 states so far.
The Ampa One device received FDA clearance in February 2025. The device costs $3000 per month and fits into the trunk of a normal car, which is a stark difference from large legacy TMS machines. BrainsWay’s Deep TMS system, for comparison, measures 81 inches tall, 27 inches wide, 27 inches deep and weighs 340 pounds. Smaller, portable TMS-like options are starting to gain more traction in the market for their feasibility to operate outside of clinic walls.
Clinician training to operate Ampa’s device is said to only require a few hours.
Demand for TMS care continues to climb and smaller-scale devices that can deliver quality outcomes at a lower cost could be the way to keep pace. Ampa’s latest funding will help it reach that demand, Dr. Don Vaughn, CEO of Ampa, said in a press release.
EarliPoint Health raises $3.5M for autism diagnoses tech
Digital autism company EarliTec Diagnostics, which rebranded in October 2025 to EarliPoint Health, recently raised $3.5 million in a late-stage venture capital funding round.
SEC filings show the money raised is debt equity. The company builds technology to aid clinicians in diagnosing autism spectrum disorder in children between the ages of 16 months and 8 years old.
EarliPoint’s last funding round was a $21.5 million Series B in 2024.
TimelyCare $2.7M Following Acquisition of Alongside
TimelyCare, a Texas-based virtual mental health provider that offers services primarily within educational environments, raised more than $2.7 million in new capital, according to an SEC filing.
The news comes less than a month after TimelyCare announced its acquisition of the AI-powered coaching platform Alongside, which offers support, skill-building and safety models to detect risk and connect students with additional support as needed. Terms of the deal were not disclosed, but Luke Hejl, TimelyCare’s CEO, described the transaction as one that would extend its “beyond moments of acute need to provide continuous, clinically grounded support that helps institutions reach more students, earlier.”
The company has been named as one of the fastest-growing in the U.S. on the Inc. 5,000 List for four consecutive years as of 2025.
Alvee Health gets $2.5M for AI platform
Alvee Health, the company behind an AI-powered platform that extracts social determinants of health data from unstructured clinical data and converts them into actionable items within workflows for resource matching, has received $2.5 million as part of a late-stage venture capital fundraise.
The data it extracts is integrated into existing customer relationship management and electronic health record systems and also features health equity dashboards and demographic data.
Alvee was founded in 2021 and initially raised a $120,000 seed round, with backing from Coyote Ventures, Alumni Ventures, MedMountain Ventures, Ideaship Fund and Mayo Clinic Platform_Accelerate.
In 2024, the company received an undisclosed investment amount from Catalyst by Wellstar and was named a recipient of the University of California, San Francisco’s Rosenman Institute ADAPT award. As part of the award, Alvee received $100,000 in non-dilutive funding, executive mentorship and collaboration opportunities with payers like Blue Shield of California and Evernorth Health Services.